The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Management of patients receiving interferon beta-1b for multiple sclerosis: Report of a consensus conference*
Abstract
Results of a double-blind, placebo-controlled study in ambulatory patients with relapsing-remitting MS showed that interferon beta-1b reduced the rate of exacerbations by one-third compared with placebo and limited new disease activity in the brain as evidenced by MRI. Interferon beta-1b, administered subcutaneously at a dosage of 0.25 mg (8 million IU) every other day is indicated for the treatment of ambulatory patients with relapsing-remitting MS. Interferon beta-1b may help a wider range of patients, but it should be prescribed only for patients with a diagnosis of clinically definite or laboratory-supported definite MS. The decision to treat a patient with interferon beta-1b should be individualized; that is, based on each patient's clinical presentation and course of MS. The most common adverse effects include (1) injection-site reactions and (2) flu-like symptoms, which are generally manageable and usually abate after the first few months of treatment. Spasticity may increase. Patients with severe depression or suicidal ideation should be monitored carefully, and symptomatic treatment should be pursued. Interferon beta-1b is contraindicated in pregnant and nursing women. Interferon beta-1b is effective in reducing the progression of total disease burden as seen on MRI in patients with MS. Its use is relatively straightforward and generally does not require alteration in the symptomatic treatment of MS. Patient education and support remain the mainstays of maintaining compliance through the early phases of therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Lewy body variant of Alzheimer's disease: A clinical and pathologic entity
Hansen, L., Salmon, D., Galasko, D., Masliah, E., Katzman, R., DeTeresa, R., Thal, L., Pay, M. M., Hofstetter, R., Klauber, M., et al. (1990) · Neurology · doi:10.1212/wnl.40.1.1 · Cited by 1,068
Cited by
The Goldman Consensus statement on depression in multiple sclerosis
Goldman Consensus Group (2005) · Multiple Sclerosis Journal · doi:10.1191/1352458505ms1162oa · Cited by 329
Multiple sclerosis: Side effects of interferon beta therapy and their management
Walther, E. U., & Hohlfeld, R. (1999) · Neurology · doi:10.1212/wnl.53.8.1622 · Cited by 304
Psychiatric Issues in Multiple Sclerosis
Chwastiak, L. A., & Ehde, D. M. (2007) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2007.07.003 · Cited by 166
Zivadinov, R., Zorzon, M., Tommasi, M. A., Nasuelli, D., Bernardi, M., Monti-Bragadin, L., & Cazzato, G. (2003) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(03)00225-9 · Cited by 81
“The side effects of IFNh therapy are reported to decrease over a few months [27,31], although a number of individuals may continue to experience side effects throughout the treatment [32].”
Background
Metadata
- Authors
- Lublin, F. D., Whitaker, J. N., Eidelman, B. H., Miller, A. E., Arnason, B. G. W., & Burks, J. S.
- Venue
- Neurology
- Published
- 1996-01
- Volume
- 46
- Issue
- 1
- Pages
- 12-18
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2085317592
- Cited by
- 170
- References
- 1
- FWCI
- 11.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Management of patients receiving interferon beta-1b for multiple sclerosis: Report of a consensus conference*. https://app.cochat.ai/papers/10.1212/wnl.46.1.12
- The paper
- Lublin, F. D., Whitaker, J. N., Eidelman, B. H., Miller, A. E., Arnason, B. G. W., & Burks, J. S. (1996). Management of patients receiving interferon beta-1b for multiple sclerosis: Report of a consensus conference*. Neurology. https://doi.org/10.1212/wnl.46.1.12
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.